Laboratoires Pierre Fabre

Pierre Fabre, XtalPi Ink AI Drug Discovery Deal in Oncology

Image
Pierre Fabre, XtalPi Ink AI Drug Discovery Deal in Oncology

Castres – November 09, 2026 -- Laboratoires Pierre Fabre and XtalPi Holdings Limited (2228.HK) have signed a drug discovery agreement that includes an upfront payment, multiple milestone payments and downstream economic participation. Neither company disclosed the financial terms.

XtalPi to design small molecules de novo against undisclosed targets

XtalPi will apply its integrated AI capabilities and robotics platform to design and deliver novel small molecule therapeutics. The research programs cover oncology, potentially dermatology, and rare diseases. The targets were not named.

Pierre Fabre takes on compound selection and clinical and commercial development

Pierre Fabre will contribute expertise in disease biology, discovery, translational research and clinical development to select and advance the most promising compounds. It will also be responsible for subsequent clinical and commercial development.

Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Image
Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

Resubmission follows April 2026 FDA alignment meeting

PFP filed the updated application after reaching agreement with the FDA during an April 2026 Type A meeting. The package includes an expanded dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, which evaluates tabelecleucel in patients with EBV+ PTLD following hematopoietic cell transplant (HCT) or solid organ transplant (SOT).